Breaking News, Financial News

3Q Financial Reports

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Merck & Co. 3Q Revenues: $5.4 billion (flat) 3Q Earnings: $940.6 (-34%) YTD Revenues: $16.6 billion (+2%) YTD Earnings: $4 billion (+13%) Comments: Worldwide sales for Singulair were $868 million for the quarter, up 25%. Combined global sales of Zetia and Vytorin, as reported by the Merck/Schering-Plough partnership, exceeded $1 billion for the quarter. Vaccine sales were $555 million, up 64% as a result of the launch of Rotateq, Zostavax and Gardasil, and the strong perf...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters